Tesaro CMO: efficacy beyond BRCA key to Zejula's future

9 October 2018

Dr Martin Huber, chief medical officer of Tesaro (Nasdaq: TSRO), spoke with The Pharma Letter about his firm’s runner in the PARP blocker field, Zejula (niraparib).

While the PARP inhibitor class has shown promise, with a range of positive clinical results, it has struggled to take off to the extent analysts had expected, despite having had multiple quarters to gain traction.

Tesaro was also forced to cut its full-year revenue guidance to $250 million to $265 million earlier in the year, with Zejula taking in $53.9 million in the second quarter.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK